Product
Pepinemab
3 clinical trials
5 indications
Indication
Alzheimer's diseaseIndication
Breast Cancer (HER2-positive)Indication
Recurrent Malignant Solid NeoplasmIndication
OsteosarcomaIndication
Malignant Solid NeoplasmClinical trial
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-ADStatus: Active (not recruiting), Estimated PCD: 2023-06-05
Clinical trial
Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-12-31